Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

IMAB

I-Mab ADR

Oct 28 • 04:00PM ET

4.64

-0.06 -1.28 %

Healthcare • Biotechnology • USA • NASD

Peers: ONC ZLAB LEGN HCM TME CANF OCGN BBIO MRNA RGEN

| Held by: SPEM BFOR EWX GXC APIE

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.71	Insider Own	19.59%	Shs Outstand	81.79M	Perf Week	-9.55%
Market Cap	367.44M	Forward P/E	-	EPS next Y	-0.52	Insider Trans	0.00%	Shs Float	63.68M	Perf Month	35.67%
Enterprise Value	205.30M	PEG	-	EPS next Q	-0.09	Inst Own	13.82%	Short Float	5.74%	Perf Quarter	128.57%
Income	-56.63M	P/S	-	EPS this Y	-180.56%	Inst Trans	3.21%	Short Ratio	1.35	Perf Half Y	471.43%
Sales	0.00M	P/B	1.93	EPS next Y	-53.96%	ROA	-17.12%	Short Interest	3.65M	Perf YTD	445.88%
Book/sh	2.41	P/C	2.22	EPS next 5Y	-	ROE	-22.44%	52W High	6.79 -31.66%	Perf Year	277.24%
Cash/sh	2.09	P/FCF	-	EPS past 3/5Y	47.28% 28.35%	ROIC	-28.41%	52W Low	0.60 679.83%	Perf 3Y	19.59%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	9.81% 13.15%	Perf 5Y	-88.62%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	72.45%	Oper. Margin	-	ATR (14)	0.59	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	22.82	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	48.93	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	22.82	EPS Q/Q	92.74%	SMA20	-6.40%	Beta	1.47	Target Price	8.33
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	3.87%	Rel Volume	1.00	Prev Close	4.70
Employees	32	LT Debt/Eq	0.01	Earnings	Aug 20 BMO	SMA200	105.57%	Avg Volume	2.71M	Price	4.64
IPO	Jan 17, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	44.44% -	Trades		Volume	2,670,445	Change	-1.28%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-03-25	Initiated	Leerink Partners	Outperform	$9
Sep-09-25	Initiated	BTIG Research	Buy	$7
Dec-09-21	Initiated	Siebert Williams Shank	Buy	$96
Jun-02-21	Initiated	Daiwa Securities	Buy
Mar-15-21	Initiated	Needham	Buy	$75
Mar-03-21	Reiterated	H.C. Wainwright	Buy	$55 → $75
Feb-25-21	Initiated	Piper Sandler	Overweight	$75
Dec-07-20	Initiated	H.C. Wainwright	Buy	$55
Jul-27-20	Initiated	Cantor Fitzgerald	Overweight	$50
Feb-12-20	Initiated	China Renaissance	Buy
Feb-11-20	Initiated	Jefferies	Buy	$16

Show Previous Ratings

Oct-22-25 12:35PM	I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025 (GlobeNewswire) -6.04%
Oct-16-25 04:05PM	I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences (GlobeNewswire) +7.01% -12.04%
Oct-15-25 08:45AM	Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge (PR Newswire)
Oct-14-25 07:00AM	I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference (GlobeNewswire)
Oct-10-25 12:00PM	I-Mab Sponsored ADR (IMAB) Is Up 24.14% in One Week: What You Should Know (Zacks)
08:00AM	Loading…
Oct-07-25 08:00AM	Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms (PR Newswire)
Oct-06-25 12:00PM	What Makes IMab (IMAB) a New Buy Stock (Zacks)
Sep-23-25 07:12PM	I-Mab (IMAB) Shows 83% Response Rate for Givastomig in Metastatic Gastric Cancer (Insider Monkey) -7.77%
Sep-08-25 08:30AM	I-Mab Announces Acceleration of Givastomig Investment and Leadership Appointments (GlobeNewswire)
Aug-28-25 12:00PM	Are You Looking for a Top Momentum Pick? Why I-Mab Sponsored ADR (IMAB) is a Great Choice (Zacks) -5.56%
Aug-25-25 07:00AM	I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee (GlobeNewswire) -5.30%
Aug-21-25 07:00AM	I-Mab to Participate in September Investor Conferences (GlobeNewswire)
Aug-20-25 07:00AM	I-Mab Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +7.36%
Aug-11-25 07:00AM	I-Mab Completes Enrollment in Planned Phase 1b Dose Expansion Study for Givastomig in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers (GlobeNewswire) +14.08%
Aug-01-25 09:02AM	Everest Medicines Expands Strategic Investment in I-MAB (PR Newswire) +30.35%
08:00AM	Loading…
08:00AM	I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares (GlobeNewswire)
Jul-17-25 07:00AM	I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health (GlobeNewswire)
Jul-14-25 07:00AM	I-Mab to Present at the BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jul-09-25 07:20AM	I-Mab Presents Promising Phase 1b Givastomig Combination Data for Gastric Cancers at ESMO GI 2025 (Insider Monkey)
Jul-02-25 11:15AM	I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025 (GlobeNewswire)
Jun-30-25 04:01PM	I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research (GlobeNewswire) -5.84%
Jun-26-25 06:30AM	I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025 (GlobeNewswire) -27.34%
Jun-18-25 07:00AM	I-Mab to Host Webinar to Recap New Givastomig Data, in Combination with Immunochemotherapy, Expected at ESMO GI 2025 (GlobeNewswire) -5.67%
Jun-12-25 07:00AM	I-Mab Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Jun-11-25 09:55AM	I-Mab Sponsored ADR (IMAB)'s Technical Outlook is Bright After Key Golden Cross (Zacks) -5.68%
Jun-06-25 12:00PM	I-Mab Sponsored ADR (IMAB) is a Great Momentum Stock: Should You Buy? (Zacks) +6.99%
Jun-03-25 07:00AM	I-Mab to Participate in the H.C. Wainwright "HCW@Home" Series (GlobeNewswire) +46.09%
May-20-25 07:00AM	I-Mab to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
May-15-25 07:00AM	I-Mab Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Apr-30-25 07:00AM	I-Mab Announces Givastomig Abstract Accepted for Oral Presentation at ESMO GI 2025 (GlobeNewswire) +15.76%
09:35AM	Loading…
Apr-14-25 09:35AM	After Plunging -20.33% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB) (Zacks) +42.81%
Apr-11-25 09:35AM	After Plunging -19.7% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB) (Zacks)
Apr-03-25 04:01PM	I-Mab Reports Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -6.19% -6.86%
Mar-26-25 07:00AM	I-Mab to Present at 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-21-25 04:30PM	I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement (GlobeNewswire)
Mar-07-25 07:00AM	I-Mab Announces Accelerated Givastomig Phase 1b Study Progress (GlobeNewswire)
Feb-18-25 07:00AM	I-Mab to Participate in Leerink Partners Global Healthcare Conference (GlobeNewswire)
Feb-04-25 07:30AM	I-Mab to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-08-25 07:00AM	I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member (PR Newswire) +11.97%
Jan-07-25 05:38AM	I-Mab pauses CD73 antibody development in pipeline reshuffle (Clinical Trials Arena) -9.04%
Jan-06-25 07:00AM	I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program (PR Newswire) +14.91%
Nov-21-24 07:00AM	I-Mab to Participate at the Piper Sandler Healthcare Conference (PR Newswire)
Nov-14-24 07:00AM	I-Mab Reports Third Quarter 2024 Results (PR Newswire)
Nov-06-24 07:00AM	I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer (PR Newswire)
Oct-31-24 07:00AM	I-Mab to Release Q3 2024 Financial Results on November 14, 2024 (PR Newswire)
Oct-30-24 07:00AM	I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024 (PR Newswire) -5.93%
Oct-28-24 07:00AM	I-Mab to Participate at the Truist Securities BioPharma Symposium (PR Newswire)
Oct-25-24 07:28AM	I-Mab Biopharmas Strategic US Transition and Pipeline Focus (TipRanks)
Oct-09-24 12:00PM	IMab (IMAB) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Sep-16-24 04:01PM	I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024 (PR Newswire)
Sep-10-24 07:00AM	I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer (PR Newswire)
Aug-28-24 07:00AM	I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates (PR Newswire) -7.14%
Aug-26-24 07:00AM	I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire) +7.00%
Aug-14-24 07:00AM	I-Mab to Release 1H 2024 Financial Results on August 28, 2024 (PR Newswire)
Aug-07-24 07:00AM	I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC) (PR Newswire)
Jul-15-24 07:30AM	I-Mab Announces Leadership Transitions (PR Newswire) -5.23%
Jun-06-24 07:00AM	I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer (PR Newswire)
04:45AM	I-Mab and BMS assess givastomig for gastric and oesophageal cancer (Pharmaceutical Technology)
Jun-05-24 07:00AM	I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers (PR Newswire)
May-23-24 05:05PM	I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024 (GlobeNewswire)
May-22-24 07:00AM	I-Mab to Participate at the Jefferies Global Healthcare Conference (PR Newswire)
May-02-24 12:00AM	Q1 2024 Summit Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Apr-30-24 07:00AM	I-MAB Filed 2023 Annual Report on Form 20-F (PR Newswire)
Apr-05-24 07:00AM	I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference (PR Newswire)
Apr-02-24 04:01PM	I-Mab Announces Closing of the Divestiture of Business Operations in China (PR Newswire)
Mar-14-24 05:00PM	I-Mab Reports Full Year 2023 Financial Results and Business Update (PR Newswire)
Mar-07-24 10:03AM	TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-21-24 01:56AM	Q4 2023 Summit Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-07-24 08:28AM	I-Mab sheds China footprint to complete transformation into US-based biotech (FierceBiotech.com)
06:29AM	UPDATE 2-Biotech firm I-Mab to divest China operations, shift focus to US (Reuters)
06:00AM	I-Mab Signs Agreement to Divest its Assets and Business Operations in China (PR Newswire)
Nov-06-23 08:00AM	I-Mab Announces Participation at Jefferies and Piper Conferences in November (PR Newswire)
Nov-02-23 08:00AM	Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN) (PR Newswire) +9.15%
Nov-01-23 08:00AM	I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023 (PR Newswire) +6.99%
Oct-16-23 08:00AM	I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023 (PR Newswire)
Oct-10-23 08:00AM	I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503 (PR Newswire) +6.38%
Oct-05-23 05:17PM	Ray Dalio on Potential US-China War and Rise of China (Insider Monkey) +6.11% +5.04%
Sep-22-23 05:03PM	UPDATE 1-AbbVie terminates deal with I-Mab to develop cancer drug (Reuters) +6.67%
Sep-05-23 08:00AM	I-Mab Announces Upcoming Participation at September Conferences (PR Newswire) -7.73%
Aug-18-23 10:55AM	I-Mab (NASDAQ:IMAB) Q2 2023 Earnings Call Transcript (Insider Monkey) -8.70%
Aug-17-23 10:30PM	Half Year 2023 I-Mab Earnings Call (Thomson Reuters StreetEvents)
06:00AM	I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates (PR Newswire)
05:25AM	Analyst Report: I-Mab (Morningstar Research)
Aug-08-23 08:00AM	I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023 (PR Newswire)
Jul-07-23 06:35PM	Masimo and Vera Therapeutics Stock See Action From Activist Investors (Barrons.com)
Jul-05-23 08:00AM	I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC (PR Newswire)
Jun-22-23 08:00AM	I-Mab Announces the Appointment of Raj Kannan as CEO (PR Newswire)
Jun-11-23 10:31AM	Retail investors account for 40% of I-Mab's (NASDAQ:IMAB) ownership, while institutions account for 17% (Simply Wall St.)
May-26-23 10:00AM	I-Mab Reveals Promising Results in Phase 1b/2 Study for Advanced Non-Small Cell Lung Cancer Treatment (Benzinga)
May-25-23 05:01PM	I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023 (PR Newswire) -5.97%
May-01-23 08:00AM	I-MAB Filed 2022 Annual Report on Form 20-F (PR Newswire)
Apr-26-23 09:16AM	I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023 (PR Newswire) -5.73%
Apr-25-23 01:46AM	I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon (PR Newswire)
Apr-24-23 09:00AM	I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China (PR Newswire) -5.07%
Apr-05-23 10:59AM	Analyst Report: I-Mab (Morningstar Research)
10:51AM	I-Mab (NASDAQ:IMAB) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-31-23 06:30AM	I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022 (PR Newswire)
Mar-20-23 08:00AM	I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update on March 31, 2023 (PR Newswire)
Mar-10-23 02:26AM	TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-09-23 05:49AM	Q4 2022 TRACON Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -6.05%

I-Mab operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zang on June 30, 2016 and is headquartered in Rockville, MD.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMAB

I-Mab ADR

Upgrade your FINVIZ experience